Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A diagnostic test for prostate cancer from gene expression profiling data.

Raphael Bueno1, Kevin R Loughlin, Martha H Powell

  • 1Thoracic Surgery Oncology Laboratory and Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115,USA. rbueno@partners.org

The Journal of Urology
|January 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Making Rounds: Our Profession's Finest Tradition.

The Canadian journal of urology·2026
Same author

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same author

Corrigendum to 'Multiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype' [Journal of Thoracic Oncology Volume 21 Issue 4 (2026) 103529].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Quantitative MRI-Based T Category in Pleural Mesothelioma: Analysis of a Large Real-World Cohort.

Academic radiology·2026
Same author

The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.

The Annals of thoracic surgery·2026
Same author

The Treatment of Metastatic Prostate Cancer: The Next Wave.

The Urologic clinics of North America·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Uro-Science.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
Same journal

Editorial Comment.

The Journal of urology·2026
See all related articles

A new gene ratio test accurately diagnoses prostate cancer, offering a simple, platform-independent method for clinical use. This approach avoids complex algorithms, aiding in early detection and potentially complementing standard pathology.

Area of Science:

  • Oncology
  • Bioinformatics
  • Molecular Diagnostics

Background:

  • Bioinformatics tools show high accuracy in tumor classification from expression profiling data.
  • Clinical application of these tools is limited by complex, non-reproducible algorithms.
  • A platform-independent method using gene expression ratios has been developed for cancer diagnosis and outcome prediction.

Purpose of the Study:

  • To apply a novel gene expression ratio method for the diagnosis of prostate cancer.
  • To develop and validate a simple, reproducible diagnostic test for prostate cancer.

Main Methods:

  • A ratio-based predictive model was developed using a training set of 32 samples.
  • The model was tested and refined on an independent set of 34 samples.

Related Experiment Videos

  • Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to validate the test on 20 clinical samples (10 normal, 10 tumor).

    • Main Results:

    • A 3-ratio test utilizing 4 genes achieved 90% accuracy in distinguishing normal prostate tissue from prostate cancer.
    • The test correctly identified all non-cancerous samples, showing no false negatives.
    • Statistical analysis (Fisher's exact test) showed significant results (p = 0.0007).

    Conclusions:

    • A validated gene ratio-based test for prostate cancer diagnosis has been developed.
    • The test is easily adaptable to clinical settings, requiring no complex software or hardware.
    • This gene ratio test could serve as a valuable adjunct to traditional histopathological methods for prostate cancer diagnosis.